Companies / Industrials
EFX
Equifax
Research & Consulting Services
Research & Consulting ServicesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health61
Growth46
Profitability56
Cash generation87
Balance sheet35
Dilution control81
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)9.6%Revenue growth (FY)6.9%Revenue CAGR (3y)5.8%Gross margin—Operating margin18.0%Net margin10.9%Free cash flow margin18.7%R&D / revenue—Stock comp / revenue1.3%Net debt / operating cash flow3.70xCurrent ratio0.60Diluted share count change-0.6%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $4.9B | $5.1B | $5.3B | $5.7B | $6.1B |
| Operating income | $1.1B | $1.1B | $934M | $1.0B | $1.1B |
| Net income | $744M | $696M | $545M | $604M | $660M |
| Operating cash flow | $1.3B | $757M | $1.1B | $1.3B | $1.6B |
| Capital expenditure | $469M | $624M | $601M | $512M | $481M |
| Free cash flow | $866M | $133M | $516M | $813M | $1.1B |
| Stock-based comp | $55M | $63M | $72M | $82M | $78M |
| Buybacks | $70M | $0 | $0 | $0 | $928M |
| Dividends | $190M | $191M | $192M | $193M | $233M |
| Cash | $225M | $285M | $217M | $170M | $181M |
| Total debt | $6.1B | $6.8B | $6.7B | $5.7B | $6.2B |
| Equity | $3.6B | $4.0B | $4.5B | $4.8B | $4.6B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.